A PHASE 1, DOSE-ESCALATION/DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF ORALLY ADMINISTERED CB-5083 IN SUBJECTS WITH LYMPHOID HEMATOLOGICAL MALIGNANCIES

Registry ID

CLC-102

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

CLEAVE BIOSCIENCES

Start date

2016-09-15

Last update

2016-04-29

Conditions

• LYMPHOID MALIGNANCIES

Related clinical trials

• A PHASE I/II STUDY OF PEMBROLIZUMAB (MK-3475) IN CHILDREN WITH ADVANCED MELANOMA OR A PD-L1 POSITIVE ADVANCED, RELAPSED OR REFRACTORY SOLID TUMOR OR LYMPHOMA (KEYNOTE-051)

View on source registry